Allergy Therapeutics plc (LON:AGY) Chief Scientific Officer Murray Skinner speaks to Proactive Investors about their Phase I clinical study of Acarovac MPL receiving official sign-off in Spain.
A total of 32 patients will receive Acarovac, which will be administered at two different doses. The trial is expected to take 12 months from start to finish.